iECURE

company

About

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

  • 251 - 500

Details

Last Funding Type
Series A
Last Funding Money Raised
$65M
Industries
Biotechnology,Genetics
Founded date
Jan 1, 2012
Number Of Employee
251 - 500
Operating Status
Active

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$115M
iECURE has raised a total of $115M in funding over 2 rounds. Their latest funding was raised on Nov 30, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 30, 2022 Series A $65M 1 Detail
Sep 9, 2021 Series A $50M 1 Versant Ventures Detail

Investments

Number of Investments
Number of Lead Investments
1
0
iECURE has made 1 investments. Their most recent investment was on Nov 29, 2022, when Flourish Fi raised $2.30M.
Date Company Name
Round Money Raised Industry Lead Investor
Nov 29, 2022 Flourish Fi
Seed $2.30M Financial Services

Investors

Number of Lead Investors
Number of Investors
1
1
iECURE is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Series A